Antengene Advances Key R&D Programs in Biotech Pipeline
SHANGHAI and HONG KONG, August 18, 2026 Antengene Corporation Limited, a commercial-stage global biotechnology company focused on innovative therapies...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI and HONG KONG, August 18, 2026 Antengene Corporation Limited, a commercial-stage global biotechnology company focused on innovative therapies...
CAMPBELL, Calif., August 18, 2026 Enlil, Inc. has introduced a four-layer governed AI architecture designed to help medical device...
